Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
Funding will support advancement of gene therapy programs in animal health and longevity science
Rejuvenate Bio, a biotechnology company developing gene therapies for age-related and chronic diseases, today announced the closing of a $6 million financing round led by VCapital, with participation from Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis.
In addition to the financing, Rejuvenate Bio and Merck Animal Health have entered into a strategic research and development collaboration focused on advancing a novel gene therapy program in animal health.
The funding will support continued development of Rejuvenate Bio’s platform and pipeline, including therapies designed to address chronic and age-associated diseases in companion animals.
